Objectives: There is little information about carbapenemase-producing (CP) Citrobacter spp. We studied the molecular epidemiology and microbiological features of CP Citrobacter spp. isolates collected in Spain (2013-15).
Introduction
The unceasing increase in infections due to carbapenemaseproducing (CP) Enterobacteriaceae (CPE) is one of the most worrying threats to the health services worldwide. Frequently, patients with CPE infections cannot be treated with effective antibiotics because of the dearth of alternative drugs. 1, 2 Thus far, the main clinical load of CPE has been due to the increasing incidence of nosocomial infections caused by Klebsiella pneumoniae, but other CP species, such as Escherichia coli, Enterobacter spp. and Serratia marcescens, have also been detected in nosocomial settings. 3, 4 Citrobacter spp., mainly Citrobacter freundii, have been recognized as opportunistic pathogens responsible for healthcareassociated infections such as urinary and respiratory tract infections. However, little information is available about CP Citrobacter spp.; very few studies have reported C. freundii producing VIM or KPC. [4] [5] [6] [7] [8] Some Enterobacteriaceae species, such as Citrobacter spp.
or Enterobacter spp., often present decreased susceptibility to carbapenems, mainly ertapenem, due to the overproduction of chromosomal AmpC b-lactamase plus reduced outer membrane permeability; 9 as a consequence, production of carbapenemases in these species may be underdiagnosed in clinical microbiology laboratories.
The aim of this study was to gain insight into the microbiological features and molecular epidemiology of CP Citrobacter spp., mainly C. freundii, submitted to the Spanish National Reference Centre of Microbiology from 2013 to 2015.
Materials and methods
This study was performed by the unrestricted and non-mandatory national Spanish Antibiotic Resistance Surveillance Programme operated by our official public health institute (Instituto de Salud Carlos III). When this nonmandatory programme was launched in 2009, all Spanish clinical microbiology laboratories and health-associated professionals were personally contacted and encouraged to submit their carbapenem-resistant Enterobacteriaceae to our antibiotic reference laboratory for molecular and epidemiological characterization. From January 2013 to December 2015, a total of 115 public hospitals (about 35% of the total Spanish public hospitals) participated in the programme. In this study we included all Citrobacter spp. isolates submitted to our reference laboratory from 2013 to 2015 suspected of being carbapenemase producers according to the EUCAST screening cut-off values for CPE. 10 Only the first isolate per patient was analysed. Isolate identification was performed using MALDI-TOF MS (Bruker Daltonik GmbH, Leipzig, Germany).
Antibiotic susceptibility testing was performed by microdilution (MicroScan, Beckman Coulter, Inc.) and interpreted according to EUCAST breakpoints. 10, 11 According to EUCAST recommendations, inhibition of carbapenemase activity was determined by using EDTA, phenyl-boronic acid and cloxacillin. In addition, all the isolates were tested with both the Carba NP method 12 and the modified Hodge test 13 with a meropenem disc containing 600 mg of cloxacillin.
The presence of genes encoding carbapenemases (bla OXA-48 , bla KPC , bla VIM , bla IMP and bla NDM ) and ESBLs (bla CTX-M , bla SHV and bla TEM ) was determined by PCR and DNA sequencing. 14, 15 The genetic relationship among the CP C. freundii isolates was elucidated by PFGE after total chromosomal DNA digestion with XbaI. 15 The genetic environment of bla VIM-1 was studied using PCR mapping and subsequent sequencing of the variable region of the class 1 integron; the genetic environment of the bla OXA-48 gene was determined by PCR as previously described. 16 All the sequences obtained were compared with those available in GenBank (GenBank accession numbers KC354801.1, EF093146, FJ627181, GU086225.1 and FN396876).
Results and discussion
During the 3 year period of the study, 119 isolates of Citrobacter spp. suspected of being carbapenemase producers according to the EUCAST screening cut-off values for CPE 10 were analysed. Sixty-three of them (52.9%) produced carbapenemases (1.5% of the 4129 CPE identified in the reference laboratory during the same period of time). An increase in the CP Citrobacter spp. isolates was observed: 1.3% in 2013 (10 out of 775), 1.7% in 2014 (25 out of 1431) and 1.5% in 2015 (28 out of 1923). The 63 CP Citrobacter spp. came from 27 Spanish hospitals located in 14 different provinces. Fifty-seven (90.5%) of them were C. freundii, four (6.3%) were Citrobacter koseri, one (1.6%) was Citrobacter amalonaticus and one (1.6%) was Citrobacter braakii. Thirty-two (50.8%) produced clinical infections as follows: 19 (59.4%) urinary tract infections, 8 (25%) wound infections, 1 (3.1%) bacteraemia and 4 (12.5%) other infections. The remaining 31 (49.2%) isolates were obtained from rectal samples.
Of the 63 CP Citrobacter spp., 37 (58.7%) produced VIM-1, 20 (31.7%) produced OXA-48, 12 (19%) produced KPC-2, 2 (3.2%) produced NDM-1 and 1 (1.6%) produced VIM-2; 9 C. freundii coproduced VIM-1 plus OXA-48. The modified Hodge test and the Carba NP test yielded positive results for all the 63 CP isolates.
Fourteen (22.2%) CP Citrobacter spp. also produced ESBLs as follows: 8 (57.1%) produced CTX-M-9 plus SHV-12 (7 of them also producing VIM-1 plus OXA-48 and 1 producing VIM-1), 2 (14.3%) produced CTX-M-9 (1 of them also producing VIM-1 plus OXA-48 and 1 producing OXA-48), 2 (14.3%) produced SHV-12 (1 of them also producing OXA-48 and 1 producing VIM-1) and 2 (14.3%) produced CTX-M-15 (both also producing NDM-1). Interestingly, of the four CP C. koseri, three of them were OXA-48 producers without ESBL production and one co-produced NDM-1 and CTX-M-15. The remaining two non-C. freundii isolates (one C. amalonaticus and one C. braakii) produced VIM-1, but not ESBLs.
Antibiotic susceptibility data are displayed in Table 1 . The OXA-48-producing isolates were more susceptible to ciprofloxacin (63.6%) and tobramycin (63.6%) than the isolates producing VIM-1 (32.1% and 0%, respectively) and KPC-2 (0% and 33%, respectively), although without statistical significance. Three isolates (4.8%) were resistant to colistin by the commercial microdilution commercial method used, but susceptible by the in-house microdilution method recommended by EUCAST (http://www.eucast. org/ast_of_bacteria/warnings/, last accessed April 2017); by PCR, all three isolates were negative for mcr-1.
Of the 63 CP Citrobacter spp., 37 (58.7%) were susceptible to imipenem, 33 (52.4%) were susceptible to meropenem, 25 (39.7%) Arana et al.
were susceptible to doripenem and 9 (14.3%) were susceptible to ertapenem (Table 1 ). These data suggest that ertapenem has the highest sensitivity for the detection of CP Citrobacter spp. and imipenem the lowest, although specificity could not be determined. However, susceptibility to carbapenems varied in relation to the carbapenemase types as follows: ertapenem susceptibility was 0% in isolates producing OXA-48, 0% in OXA-48/VIM-1 producers, 16.7% in KPC-2 producers and 25% in VIM-1 producers, while imipenem susceptibility was 91%, 77.8%, 33.3% and 64.3%, respectively. Interestingly, 8 (12.7%) of the 63 CP Citrobacter spp. isolates (6 of them producing VIM-1 and 2 producing KPC-2) were susceptible to the four carbapenems tested according to EUCAST clinical breakpoints, 11 but they were suspected of being CP by the screening cut-off values recommended by EUCAST. 10 According to CLSI breakpoints, 13 four of these eight isolates had an intermediate susceptibility to imipenem (MIC " 2 mg/L), but were susceptible to the other three carbapenems.
PFGE analysis revealed a high degree of genetic diversity because 44 different PFGE patterns were obtained from the 53 CP C. freundii analysed. However, four well-defined clusters were detected with a genetic linkage 84% (Figure 1 ). Cluster 1 (C1) included nine VIM-1-producing C. freundii (eight of them also coproducing OXA-48) isolated from a single hospital (East Spanish area); all nine isolates also co-produced ESBLs (eight CTX-M-9 plus SHV-12 and one CTX-M-9). Cluster 2 contained five VIM-1-producing C. freundii isolated from three different hospitals located in three neighbouring provinces, two of them very close together. Cluster 3 consisted of five KPC-2-producing C. freundii isolated from two hospitals of the same province in the central Spanish area. Cluster 4 included four VIM-1-producing C. freundii isolated from the same hospital in the central Spanish area. These results point to a clonal dissemination of CP C. freundii within the same hospital or between different hospitals, but also to a polyclonal dissemination since 30 of the CP isolates had non-related PFGE patterns.
Interestingly, the nine C1 C. freundii isolates were collected from faecal carriers admitted to the onco-haematology unit of a university hospital. In the same hospital, during 2013-15, a total of 54 patients had rectal cultures positive for C. freundii co-producing VIM-1 plus OXA-48 although no clinical infections caused by this pathogen were observed; the 9 C1 isolates included in the study constituted a representative sample of the 54 mentioned isolates. The first identified carrier was a 60-year-old male diagnosed with AML transferred from another Spanish hospital in October 2013; this patient had a rectal culture positive for C. freundii producing VIM-1 plus OXA-48 in November 2013.
Because cluster C1 contained the highest number of CP isolates also producing two different types of carbapenemases, the genetic environments of bla VIM-1 and bla OXA-48 were studied in two representative C1 isolates. In the two isolates, VIM-1 was located in a class 1 integron containing five resistance genes (intI-bla VIM-1 -aacA4-dfrB1-aadA1-catB2-qacED1/sul1). Also in the two isolates, upstream of bla OXA-48 , IS1999 was disrupted by the IS1R element, but downstream of bla OXA-48 this gene was flanked by IS1999 without the IS1R element, indicating the presence of a Tn1999.2. 16 OXA-48 and VIM-1 are the most frequent carbapenemases detected in Spain and K. pneumoniae, Enterobacter cloacae and E. coli are the most affected species. 3, 4, 14 However, very little information is available about CP C. freundii. 5, 7, 8 In addition, while some studies have described the co-production of two carbapenemases such as NDM-1 plus VIM-1 in C. freundii, K. pneumoniae and E. cloacae 17, 18 or KPC-2 plus VIM-2 in K. pneumoniae, 19 very few studies have reported the co-production of VIM-1 plus OXA-48 17, 20 and none of them in C. freundii. We detected a moderate increase in CP Citrobacter spp. in Spain between 2013 and 2015; in addition, our data revealed several remarkable findings: (i) clonal and polyclonal spread of CP C. freundii across different geographical areas and hospitals; (ii) carriage of five different carbapenemase types by four species of Citrobacter spp., especially C. freundii; (iii) detection of C. freundii co-producing OXA-48 plus VIM in carriers admitted to an onco-haematology hospital unit; and (iv) detection of carbapenemases in carbapenem-susceptible isolates by EUCAST clinical breakpoints, a finding that could have important clinical and epidemiological consequences. In our opinion, all these findings are of clinical, microbiological and epidemiological interest and deserve active surveillance. 
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